曲妥珠单抗美坦新联合卡培他滨对比单药治疗经治HER2阳性转移性乳腺癌的1期及随机2期试验
该研究包含1期剂量探索和2期随机对照两部分。1期确定卡培他滨联合T-DM1的最大耐受剂量为700 mg/m2(每日两次)。
要点
- 1期确定卡培他滨联合T-DM1的最大耐受剂量为700 mg/m2(每日两次,第1-14天,3周周期)。
- 联合组3-4级不良事件发生率为44%,单药组为41%,未报告5级不良事件。
核心结论
- 在经治HER2阳性转移性乳腺癌患者中,T-DM1联合卡培他滨相比T-DM1单药并未显著提高客观缓解率。
- 联合组不良事件更多,但未观察到预期外毒性。
研究设计与样本
- 1期采用3+3设计评估卡培他滨联合T-DM1的最大耐受剂量,卡培他滨设750、700、650 mg/m2三个剂量水平。
- 2期为开放标签、随机、国际多中心研究,将转移性乳腺癌患者按1:1随机分配至联合组(n=81)或T-DM1单药组(n=80)。
- 1期转移性乳腺癌队列接受卡培他滨(每日两次,第1-14天,3周周期)联合T-DM1 3.6 mg/kg每3周;局部晚期/转移性胃癌队列接受卡培他滨(转移性乳腺癌1期最大耐受剂量,必要时降阶梯)联合T-DM1 2.4 mg/kg每周。
- 2期主要终点为研究者评估的客观缓解率。
主要发现
- 1期确定卡培他滨联合T-DM1的最大耐受剂量为700 mg/m2(每日两次),基于11例转移性乳腺癌和6例局部晚期/转移性胃癌患者的剂量限制性毒性评估。
- 联合组82例中78例(95%)报告不良事件,其中36例(44%)发生3-4级不良事件;单药组78例中69例(88%)报告不良事件,其中32例(41%)发生3-4级不良事件;未报告5级不良事件。
关键数值与推荐
- 卡培他滨联合T-DM1的1期最大耐受剂量为700 mg/m2(每日两次,第1-14天,3周周期)。
临床怎么用
- 对于经治HER2阳性转移性乳腺癌,在T-DM1基础上加用卡培他滨未显示客观缓解率获益,且不良事件增加,不支持该联合方案作为常规选择。
- 卡培他滨联合T-DM1的最大耐受剂量为700 mg/m2(每日两次),可作为未来联合方案设计的参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: ERBB2 (HER2)-targeted therapy provides benefits in metastatic breast cancer (mBC) and gastric cancer, but additional treatments are needed to maximize efficacy and quality of life. OBJECTIVE: To determine maximum tolerated doses (MTDs) of trastuzumab emtansine (T-DM1) plus capecitabine in patients with previously treated ERBB2-positive mBC and locally advanced/metastatic gastric cancer (LA/mGC) (phase 1) and the efficacy and safety of this combination vs T-DM1 alone in patients with mBC (phase 2). DESIGN, SETTING, AND PARTICIPANTS: The MTD in phase 1 was assessed using a 3 + 3 design with capecitabine dose modification. Phase 2 was an open-label, randomized, international multicenter study of patients with mBC treated with T-DM1 plus capecitabine or T-DM1 alone. Eligible patients had previously treated ERBB2-positive mBC or LA/mGC with no prior chemotherapy treatment for advanced disease. INTERVENTIONS: Patients in the phase 1 mBC cohort received capecitabine (750 mg/m2, 700 mg/m2, or 650 mg/m2 twice daily, days 1-14 of a 3-week cycle) plus T-DM1 3.6 mg/kg every 3 weeks. Patients with LA/mGC received capecitabine at the mBC phase 1 MTD, de-escalating as needed, plus T-DM1 2.4 mg/kg weekly. In phase 2, patients with mBC were randomized (1:1) to receive capecitabine (at the phase 1 MTD) plus T-DM1 or T-DM1 alone. MAIN OUTCOMES AND MEASURES: The phase 1 primary objective was to identify the MTD of capecitabine plus T-DM1. The phase 2 primary outcome was investigator-assessed overall response rate (ORR). RESULTS: In phase 1, the median (range) age was 54.0 (37-71) and 57.5 (53-70) years for patients with mBC and patients with LA/mGC, respectively. The capecitabine MTD was identified as 700 mg/m2 in 11 patients with mBC and 6 patients with LA/mGC evaluable for dose-limiting toxic effects. In phase 2, between October 2014 and April 2016, patients with mBC (median [range] age, 52.0 [28-80] years) were randomized to receive combination therapy (n = 81) or T-DM1 (n = 80). The ORR was 44% (36 of 81 patients) and 36% (29 of 80 patients) in the combination and T-DM1 groups, respectively (difference, 8.2%; 90% CI, -4.5 to 20.9; P = .34; clinical cutoff, May 31, 2017). Adverse events (AEs) were reported in 78 of 82 patients (95%) in the combination group, with 36 (44%) experiencing grade 3-4 AEs, and 69 of 78 patients (88%) in the T-DM1 group, with 32 (41%) experiencing grade 3-4 AEs. No grade 5 AEs were reported. CONCLUSIONS AND RELEVANCE: Adding capecitabine to T-DM1 did not statistically increase ORR associated with T-DM1 in patients with previously treated ERBB2-positive mBC. The combination group reported more AEs, but with no unexpected toxic effects. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01702558.
引用
- Cortés J, Diéras V, Lorenzen S, et al. Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial. JAMA Oncol. 2020. PMID: 32584367. doi:10.1001/jamaoncol.2020.1796
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。